Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centogene AG - |
RCV001809172 | SCV002059620 | uncertain significance | Spinocerebellar ataxia type 5 | 2021-03-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002541480 | SCV003558398 | uncertain significance | Inborn genetic diseases | 2021-03-26 | criteria provided, single submitter | clinical testing | The c.5468_5470dupAGC (p.Q1823dup) alteration is located in exon 26 (coding exon 25) of the SPTBN2 gene. The alteration consists of an in-frame duplication of 3 nucleotides from position 5468 to 5470, resulting in the duplication of <NA> residues. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003772266 | SCV004659294 | uncertain significance | not provided | 2022-12-13 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 1333957). This variant has not been reported in the literature in individuals affected with SPTBN2-related conditions. This variant is not present in population databases (gnomAD no frequency). This variant, c.5468_5470dup, results in the insertion of 1 amino acid(s) of the SPTBN2 protein (p.Gln1823dup), but otherwise preserves the integrity of the reading frame. |